Actively Recruiting
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
Led by Zhongda Hospital · Updated on 2024-09-19
188
Participants Needed
1
Research Sites
85 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
CONDITIONS
Official Title
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of hepatocellular carcinoma at Chinese Liver Cancer Staging Scheme stage IIb to IIIa, or stage Ia to IIa if unsuitable or unwilling for surgery, transplantation, or ablation
- Liver function classified as Child-Pugh A or B
- Eastern Cooperative Oncology Group score between 0 and 2
- At least one measurable liver tumor lesion between 1 and 10 cm that has not been embolized
- Willingness to participate and sign informed consent
You will not qualify if you...
- Target lesion previously embolized or requiring other combined treatments
- Diffuse liver cancer or cancer with spread outside the liver
- Blood clotting problems with prolonged prothrombin time beyond normal by more than 3 seconds
- Severe kidney dysfunction with creatinine clearance below 30 ml/min
- Severe liver dysfunction with enzymes exceeding normal limits by 5 times
- Complete blockage of the main portal vein without collateral blood supply
- Untreatable arteriovenous or portal vein fistulas
- Severe weight loss (cachexia) or hepatic encephalopathy
- Active infection present
- Low white blood cell count below 3.0x10^9/L or platelet count below 50x10^9/L that cannot be corrected
- Pregnant or breastfeeding women
- Difficulty in selective catheterization during treatment
- High risk of embolization outside target area
- Severe allergy to contrast agents or embolic materials
- Currently participating in another clinical trial
- Judged unsuitable by the investigator for other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Gao-Jun Teng
Nanjing, China
Actively Recruiting
Research Team
L
Lei Zhang, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here